Bayer faces an uphill fight with finerenone
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
Crispr valuation is no match for reality
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
Roche buys into Prothena... kind of
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Aptinyx data reveal statistical trauma
An attempt to abrogate the placebo response does not seem to have gone as planned.
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
Toxicity concerns now hit the Covid antibody approach
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Primary omecamtiv win is not enough
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Two Covid-19 antibodies look better than one for Lilly
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
Bristol scores early
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
